A Phase 3 interventional study of LX101 in Inherited Retinal Dystrophy Associated With RPE65 Mutations, sponsored by Innostellar Biotherapeutics Co.,Ltd. Active, not recruiting at 4 sites in China. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Innostellar Biotherapeutics Co.,Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Retinal Dystrophies with a site in China — 6 open to participants now, 9 under way, 1 of them phase 3. Retinal Dystrophies · China.
Among the 10 studies in Retinal Dystrophies with a site in China, this one is one of 2 that started in 2023, is the only one in phase 3, and was the 8th registered.
60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.
Browse Retinal Dystrophies studies →6 of the 10 studies in Retinal Dystrophies with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18–55
Zhongmou Therapeutics · Sites in China
Healthy volunteers
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 4+
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in China, United States, Australia
Ages 18–65
Frontera Therapeutics · Sites in China
Ages 8–45
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 1
First in 2018; this study’s year is marked. 2 started in 2023.
This study's enrollment of 30 is above the median of 18 across 34 interventional studies indexed under Retinal Dystrophies.
Median enrollment 9 across the 7 interventional studies, 500 across the 3 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 7 most frequent:
Innostellar Biotherapeutics Co.,Ltd is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Innostellar Biotherapeutics Co.,Ltd has 3 studies filed under Retinal Dystrophies — fewer than ten, so there is no comparison to draw.
4 of the studies in Retinal Dystrophies with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05294978Institute of Molecular and Clinical Ophthalmology BaselEyeConic: Qualification for Cone-Optogenetics | 2026-12 |
| NCT07063030Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineA Study of LX107 Gene Therapy in AIPL1-IRD Patients | 2026-12-31 |
| NCT07085533Zhongmou TherapeuticsNatural History Study of Inherited Retinal Diseases | 2027-06-04 |
| NCT07656753Peking Union Medical College HospitalSafety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Retinal Dystrophies with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy. This is an open-label, multicenter, randomized controlled Phase III clinical trial. Subjects were randomly assigned in a 1:1 ratio to either the intervention group or the control group. Subjects in the intervention group received subretinal injection of LX101, while those in the control group received no treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with biallelic RPE65 mutation-associated inherited retinal dystrophy.
Subjects are 6 years of age or older.
Visual acuity of ≤ 20/63 or visual field less than 20 degrees in the eye to be injected.
Exclusion Criteria:
Pre-existing eye conditions that would interfere with interpretation of study endpoints.
Active intraocular or periocular infections in the study eye.
Lacking of sufficient surviving retinal cells.
Prior ocular surgery within six months.
Complicating systemic diseases or abnormal baseline laboratory values.
Pre-existing systemic diseases that should not discontinue the use of any retinal toxic compounds.
Complicating systemic diseases or clinically significant abnormal baseline laboratory values.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetic: LX101
Subretinal administration of LX101 to the study eye
Mobility Test
Changes in functional vision from baseline, determined by mobility test score
Time frame: 12 months
Full-field Light Sensitivity Threshold (FST) Test
Changes in light sensitivity from baseline, assessed by FST in log cd.s/m2
Time frame: 6 months、12 months
Visual Acuity
Changes in visual acuity from baseline, based on the ability to read letters using the Early Treatment Diabetic Retionpathy Study (ETDRS) chart
Time frame: 6 months、12 months
Mobility Test
Changes in functional vision from baseline, determined by mobility test score
Time frame: 6 months
Safety: Incidence of adverse events (AEs) and serious adverse events (SAEs)
Incidence of ocular and non-ocular AEs and SAEs following LX102 subretinal injection
Time frame: 12 months
Ran from Sep 2023 to primary completion in Aug 2025, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Innostellar Biotherapeutics Co.,Ltd